ATE280823T1 - Verfahren zur inaktivierung vom umhüllten viren in einem viruspräparat mit adenoviren - Google Patents

Verfahren zur inaktivierung vom umhüllten viren in einem viruspräparat mit adenoviren

Info

Publication number
ATE280823T1
ATE280823T1 AT99403194T AT99403194T ATE280823T1 AT E280823 T1 ATE280823 T1 AT E280823T1 AT 99403194 T AT99403194 T AT 99403194T AT 99403194 T AT99403194 T AT 99403194T AT E280823 T1 ATE280823 T1 AT E280823T1
Authority
AT
Austria
Prior art keywords
inactivation
adenoviruses
viral preparation
preparation
virus
Prior art date
Application number
AT99403194T
Other languages
English (en)
Inventor
David Gaillac
Michel Koehl
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE280823T1 publication Critical patent/ATE280823T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C12N2710/10363—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
AT99403194T 1998-12-21 1999-12-17 Verfahren zur inaktivierung vom umhüllten viren in einem viruspräparat mit adenoviren ATE280823T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9816147A FR2787465A1 (fr) 1998-12-21 1998-12-21 Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes

Publications (1)

Publication Number Publication Date
ATE280823T1 true ATE280823T1 (de) 2004-11-15

Family

ID=9534248

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99403194T ATE280823T1 (de) 1998-12-21 1999-12-17 Verfahren zur inaktivierung vom umhüllten viren in einem viruspräparat mit adenoviren

Country Status (11)

Country Link
US (2) US7026154B1 (de)
EP (1) EP1016711B1 (de)
JP (1) JP4459353B2 (de)
AT (1) ATE280823T1 (de)
AU (1) AU769121B2 (de)
CA (1) CA2292922C (de)
DE (1) DE69921435T2 (de)
DK (1) DK1016711T3 (de)
ES (1) ES2230820T3 (de)
FR (1) FR2787465A1 (de)
PT (1) PT1016711E (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1420065A4 (de) * 2001-08-02 2005-03-09 Anges Mg Inc Verfahren zur herstellung einer inaktivierten virushülle
US7056723B2 (en) * 2001-12-20 2006-06-06 Bavarian Nordic A/S Method for the recovery and purification of poxviruses from infected cells
DE602004031681D1 (de) 2003-07-21 2011-04-14 Transgene Sa Multifunktionelle Cytokine
US20050197496A1 (en) * 2004-03-04 2005-09-08 Gtc Biotherapeutics, Inc. Methods of protein fractionation using high performance tangential flow filtration
AU2005229674B2 (en) * 2004-11-18 2010-11-04 Kedrion Melville Inc. Low concentration solvent/detergent process of immuneglobulin with pre-treatment
US20060130159A1 (en) * 2004-12-09 2006-06-15 Nick Masiello Method of purifying recombinant MSP 1-42 derived from Plasmodium falciparum
US7531632B2 (en) * 2006-02-16 2009-05-12 Gtc Biotherapeutics, Inc. Clarification of transgenic milk using depth filtration
PE20081723A1 (es) 2007-01-30 2008-12-14 Transgene Sa Vacuna contra el papilomavirus
MX2011007386A (es) 2009-01-20 2011-08-03 Transgene Sa Icam-1 soluble como un biomarcador para la prediccion de una respuesta terapeutica.
WO2010108908A1 (en) 2009-03-24 2010-09-30 Transgene Sa Biomarker for monitoring patients
JP5661738B2 (ja) 2009-04-17 2015-01-28 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． 患者をモニターするためのバイオマーカー
CA2767458A1 (en) 2009-07-10 2011-01-13 Bruce Acres Biomarker for selecting patients and related methods
BR112012002628B1 (pt) 2009-08-07 2021-09-08 Transgene Sa Composição imunogênica, molécula de ácido nucleico, vetor, partícula viral infecciosa, micro-organismo transgênico, composição, usos da composição imunogênica e kit de partes
JP2013523175A (ja) 2010-04-14 2013-06-17 イーエムディー・ミリポア・コーポレーション 高力価、高純度のウイルスストックの作製方法及びその使用方法
US9029517B2 (en) 2010-07-30 2015-05-12 Emd Millipore Corporation Chromatography media and method
SG191781A1 (en) * 2010-12-30 2013-08-30 Lab Francais Du Fractionnement Glycols as pathogen inactivating agents
EP3587455A1 (de) 2012-10-23 2020-01-01 Emory University Gm-csf- und il-4-konjugate, zusammensetzungen und zugehörige verfahren
US10449517B2 (en) 2014-09-02 2019-10-22 Emd Millipore Corporation High surface area fiber media with nano-fibrillated surface features
US20170298091A1 (en) 2014-12-08 2017-10-19 Emd Millipore Corporation Mixed Bed Ion Exchange Adsorber
ES3011733T3 (en) 2015-02-13 2025-04-08 Transgene Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
EP3452081A1 (de) 2016-05-04 2019-03-13 Transgene SA Kombinationstherapie mit cpg-tlr9-liganden
EP3522920A2 (de) 2016-10-10 2019-08-14 Transgene SA Immuntherapeutisches produkt und mdsc-modulator-kombinationstherapie
JP7432506B2 (ja) 2017-10-30 2024-02-16 武田薬品工業株式会社 脂質エンベロープウイルスを不活化するための環境適合性の界面活性剤
US11690869B2 (en) * 2020-04-23 2023-07-04 Johnson & Johnson Consumer Inc. Methods of inhibiting enveloped viruses using low molecular weight hydrophobically modified polymers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2007545A1 (en) * 1989-01-13 1990-07-13 Yahiro Uemura Production method for protein-containing composition
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6281010B1 (en) * 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
DE19623293C2 (de) * 1996-06-11 1998-10-22 Biotest Pharma Gmbh Nicht-immunogene Faktor VIII-enthaltende Zusammensetzung und ein Verfahren zu ihrer Herstellung
ATE353956T1 (de) * 1996-12-13 2007-03-15 Schering Corp Methoden zur virus-reinigung
DE19709186C2 (de) * 1997-03-06 1999-10-14 Medigene Ag Filtrationsverfahren zur Trennung von Viren

Also Published As

Publication number Publication date
AU769121B2 (en) 2004-01-15
US7026154B1 (en) 2006-04-11
JP2000201673A (ja) 2000-07-25
DK1016711T3 (da) 2005-03-07
JP4459353B2 (ja) 2010-04-28
AU6535899A (en) 2000-06-22
ES2230820T3 (es) 2005-05-01
US7378265B2 (en) 2008-05-27
DE69921435D1 (de) 2004-12-02
EP1016711B1 (de) 2004-10-27
FR2787465A1 (fr) 2000-06-23
CA2292922A1 (fr) 2000-06-21
US20060166345A1 (en) 2006-07-27
DE69921435T2 (de) 2006-03-02
PT1016711E (pt) 2005-02-28
EP1016711A1 (de) 2000-07-05
CA2292922C (fr) 2011-05-31

Similar Documents

Publication Publication Date Title
DE69921435D1 (de) Verfahren zur Inaktivierung vom umhüllten Viren in einem Viruspräparat mit Adenoviren
GB2199328B (en) Use of a 5' untranslated leader sequence of an rna virus to enhance translation
ATE188740T1 (de) Viruspartikel mit veraendertem wirtspektrum
DE3680130D1 (de) Verfahren zur vireninaktivierung in gamma-globulin durch waermebehandlung.
DE59501599D1 (de) Verfahren zur Herstellung von Propandiol-1,2
DE69201952D1 (de) Verwendung eines enzymhaltigen granulates und verfahren zur herstellung von einem pelletisierten futter.
EP0864646A3 (de) Verfahren zur Inaktivierung von lipidumhüllten Viren
DE68928956D1 (de) Verfahren zur Herstellung von optisch aktivem 1,3-Butanediol
DE69526182D1 (de) Verfahren zur Herstellung von Trehalosederivaten
DE69325948D1 (de) Entfernung von Antikörpern aus von Blut stammenden Zusammensetzungen unter Erhalt von Gerinnungsfaktoren
DE69514865D1 (de) Verfahren zur Herstellung von L-Asparaginsäure
DE69432158D1 (de) Verfahren zur Herstellung von optisch aktiven 2-Amino-1-phenylethanol Derivaten
DE69124769D1 (de) Verfahren zur Herstellung von (1'R,3S)-3-(1'-hydroxy-ethyl)-Azetidin-2-on und deren Derivaten
GB1488774A (en) Hepatitis b antigen and method of producing it
DE69005542D1 (de) Verfahren zur Herstellung von 3-Pentensäure.
ATE71110T1 (de) Verfahren zur reinigung eines proteins.
DE68915310D1 (de) Verfahren zur Herstellung von enantiomerischen homogenen Aminopyrrolidinyl-naphthyridin- und Quinoloncarbonsäuren.
DE59502572D1 (de) Verfahren zur Herstellung von 2-Halogenpyridinaldehyden
FI880636A7 (fi) Menetelmä vaipallisten virusten inaktivoimiseksi solun avulla in vitro valmistetuissa proteiinivalmisteissa.
DE59004380D1 (de) Verfahren zur Herstellung von alpha-Fluoracrylsäurederivaten und neue 1,1-Difluor-2-halogenethyl-(halogen) methyl-ketone.
DE69109243D1 (de) Verfahren zur Herstellung von L-Tryptophan und L-Threonine.
DE59309002D1 (de) Verfahren zur Herstellung von 6-Chlor-(6H)-dibenz-(c,e)(1,2)-oxaphosphorin
DE69019843D1 (de) Verfahren zur Herstellung von NADH-Oxydase.
DE59500712D1 (de) Verfahren zur Herstellung von 4,6-Diaminoresorcin
ATE74162T1 (de) Verfahren zur erhaltung und vermehrung von defekten, nicht-infektioesen virusgenomen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1016711

Country of ref document: EP